MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ph14060561

Медицинская библиотека · Pharmaceuticals (Basel, Switzerland) · 2021

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.

Vodošek Hojs Nina, Bevc Sebastjan, Ekart Robert, Piko Nejc, Petreski Tadej, Hojs Radovan

СтатьяОбзорПеревод в очереди

Аннотация

Diabetes mellitus is a global health issue and main cause of chronic kidney disease. Both diseases are also linked through high cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) is present in up to 40% of diabetic patients; therefore, prevention and treatment of DKD are of utmost importance. Much research has been dedicated to the optimization of DKD treatment. In the last few years, mineralocorticoid receptor antagonists (MRA) have experienced a renaissance in this field with the development of non-steroidal MRA. Steroidal MRA have known cardiorenal benefits, but their use is limited by side effects, especially hyperkalemia. Non-steroidal MRA still block the damaging effects of mineralocorticoid receptor overactivation (extracellular fluid volume expansion, inflammation, fibrosis), but with fewer side effects (hormonal, hyperkalemia) than steroidal MRA. This review article summarizes the current knowledge and newer research conducted on MRA in DKD.

Для цитирования: Vodošek Hojs Nina, Bevc Sebastjan, Ekart Robert, Piko Nejc, Petreski Tadej, Hojs Radovan. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.. Pharmaceuticals (Basel, Switzerland). 2021. DOI: 10.3390/ph14060561.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.